The Singapore-based tech company plans to present a prototype non-invasive glucose monitoring platform with two complementary device form factors. It features a handheld device for fast, non-invasive spot checks. Additionally, it has a wearable device for continuous glucose trend monitoring throughout the day.
Both prototypes aim to deliver glucose insights without fingersticks or invasive sensors. The company could join the growing class of companies bringing these types of technologies to people with diabetes. That list includes Biolinq, which received FDA clearance for its non-invasive biosensor last fall. Other potential players include LifePlus, GlucoModicum and PreEvnt, among others.
Sensura said it designed the handheld prototype for both clinical and home settings. It enables rapid, non-invasive spot measurements. Meanwhile, the wearable device offers continuous, real-time glucose trend insights, like a traditional continuous glucose monitor (CGM).
The company said its offering aims to reduce long-term user burden while supporting sustained engagement. The prototype combines proprietary optical sensing technology, custom chip architecture and AI driven analytics.
“Long-term adherence remains one of the most significant challenges in glucose monitoring,” said Hongzhi Zheng, founder and CEO of Sensura. “When monitoring is painful or inconvenient, people are far less likely to use it consistently. Our goal is to remove those barriers and make continuous health monitoring easier to sustain in everyday life.”
